Comerica Bank’s Immunogen Inc IMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-25,379
| Closed | -$752K | – | 3850 |
|
|
2023
Q4 | $752K | Hold |
25,379
| – | – | ﹤0.01% | 1674 |
|
|
2023
Q3 | $403K | Buy |
+25,379
| New | +$422K | ﹤0.01% | 1887 |
|
|
2022
Q4 | $56K | Sell |
12,500
-637
| -5% | -$3.45K | ﹤0.01% | 2113 |
|
|
2022
Q3 | $79K | Hold |
13,137
| – | – | ﹤0.01% | 2101 |
|
|
2022
Q2 | $67K | Sell |
13,137
-66
| -0.5% | -$287 | ﹤0.01% | 2128 |
|
|
2022
Q1 | $68K | Hold |
13,203
| – | – | ﹤0.01% | 2143 |
|
|
2021
Q4 | $72K | Buy |
13,203
+59
| +0.4% | +$367 | ﹤0.01% | 2136 |
|
|
2021
Q3 | $78K | Sell |
13,144
-5,603
| -30% | -$32.4K | ﹤0.01% | 2183 |
|
|
2021
Q2 | $94K | Hold |
18,747
| – | – | ﹤0.01% | 2303 |
|
|
2021
Q1 | $146K | Sell |
18,747
-725
| -4% | -$5.92K | ﹤0.01% | 2280 |
|
|
2020
Q4 | $143K | Sell |
19,472
-10,249
| -34% | -$59.8K | ﹤0.01% | 2272 |
|
|
2020
Q3 | $162K | Buy |
29,721
+10,771
| +57% | +$43.5K | ﹤0.01% | 2219 |
|
|
2020
Q2 | $85K | Sell |
18,950
-184
| -1% | -$783 | ﹤0.01% | 2228 |
|
|
2020
Q1 | $78K | Buy |
19,134
+1,931
| +11% | +$8.44K | ﹤0.01% | 2190 |
|
|
2019
Q4 | $84K | Sell |
17,203
-186
| -1% | -$631 | ﹤0.01% | 2246 |
|
|
2019
Q3 | $46K | Sell |
17,389
-36
| -0.2% | -$96 | ﹤0.01% | 2249 |
|
|
2019
Q2 | $39K | Buy |
17,425
+193
| +1% | +$456 | ﹤0.01% | 2273 |
|
|
2019
Q1 | $47K | Hold |
17,232
| – | – | ﹤0.01% | 2251 |
|
|
2018
Q4 | $83K | Buy |
17,232
+43
| +0.3% | +$261 | ﹤0.01% | 2218 |
|
|
2018
Q3 | $107K | Sell |
17,189
-1,979
| -10% | -$19K | ﹤0.01% | 2224 |
|
|
2018
Q2 | $192K | Buy |
19,168
+799
| +4% | +$8.42K | ﹤0.01% | 2203 |
|
|
2018
Q1 | $188K | Buy |
18,369
+2,000
| +12% | +$19.8K | ﹤0.01% | 2202 |
|
|
2017
Q4 | $137K | Buy |
16,369
+545
| +3% | +$3.36K | ﹤0.01% | 2221 |
|
|
2017
Q3 | $91K | Hold |
15,824
| – | – | ﹤0.01% | 2229 |
|
|
2017
Q2 | $100K | Sell |
15,824
-1,243
| -7% | -$5.69K | ﹤0.01% | 2160 |
|
|
2017
Q1 | $74K | Hold |
17,067
| – | – | ﹤0.01% | 2176 |
|
|
2016
Q4 | $41K | Buy |
17,067
+2,927
| +21% | +$5.88K | ﹤0.01% | 2174 |
|
|
2016
Q3 | $36K | Buy |
14,140
+1,243
| +10% | +$3.62K | ﹤0.01% | 2092 |
|
|
2016
Q2 | $39K | Hold |
12,897
| – | – | ﹤0.01% | 2076 |
|
|
2016
Q1 | $119K | Sell |
12,897
-202
| -2% | -$1.71K | ﹤0.01% | 2036 |
|
|
2015
Q4 | $141K | Sell |
13,099
-412
| -3% | -$5.07K | ﹤0.01% | 2002 |
|
|
2015
Q3 | $130K | Sell |
13,511
-14,011
| -51% | -$205K | ﹤0.01% | 1997 |
|
|
2015
Q2 | $396K | Buy |
27,522
+13,985
| +103% | +$154K | ﹤0.01% | 1992 |
|
|
2015
Q1 | $121K | Sell |
13,537
-13,705
| -50% | -$99.3K | ﹤0.01% | 2008 |
|
|
2014
Q4 | $166K | Buy |
27,242
+13,868
| +104% | +$127K | ﹤0.01% | 2025 |
|
|
2014
Q3 | $141K | Sell |
13,374
-570
| -4% | -$6.45K | ﹤0.01% | 2045 |
|
|
2014
Q2 | $165K | Sell |
13,944
-6,848
| -33% | -$86K | ﹤0.01% | 2068 |
|
|
2014
Q1 | $311K | Buy |
20,792
+212
| +1% | +$3.34K | ﹤0.01% | 2028 |
|
|
2013
Q4 | $302K | Sell |
20,580
-41,054
| -67% | -$631K | ﹤0.01% | 2027 |
|
|
2013
Q3 | $1.05M | Buy |
61,634
+2,362
| +4% | +$41.5K | 0.01% | 1617 |
|
|
2013
Q2 | $984K | Buy |
+59,272
| New | +$961K | 0.01% | 1398 |
|
Other funds holding IMGN
Comerica Bank's IMGN Position: Q1 2024 in Review
Comerica Bank sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 25,379 shares — an estimated $752K sold.
Comerica Bank first reported a position in IMGN in Q2 2013 and held it in 41 quarters. The position peaked at $1.05M in Q3 2013. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.
- Comerica Bank reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
- Comerica Bank sold 25,379 Immunogen Inc shares in Q1 2024, an estimated $752K.
- Comerica Bank first reported a position in Immunogen Inc in Q2 2013 and held it in 41 quarters.
- Comerica Bank's Immunogen Inc position peaked at $1.05M in Q3 2013.
- 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.
Based on Comerica Bank's 13F filing for Q1 2024, filed 16 May 2024.